Vaccines and Medicines that Prevent Infection and Antivirals that reduce risks
New Intra-nasal Vaccine now entering clinical trials
"The vaccine offers potent protection against transmission, prevents reinfection and the spread of the virus, while also reducing the generation of new variants," Dr. Liu said.
"Unlike the mRNA vaccine which targets only the spike protein, CDO-7N-1 induces immunity to all major SARS-CoV-2 proteins and is highly effective against all major variants to date.
"Importantly, the vaccine remains stable at 4°C for seven months, making it ideal for low- and middle-income countries."
The vaccine has been licensed to Indian Immunologicals Ltd, a major vaccine manufacturer.
New Antiviral approved for emergency use in US
March 2024
Ensitrelvir (known in Japan as Xocova®), an oral antiviral drug for COVID-19 suppresses the replication of SARS-CoV-2New Medication to Prevent COVID Infection and Reverse some effects of Long COVID
Next step is beginning clinical trials.
Scientists Discover A Receptor that Blocks COVID-19 Infection
February 2023
LRRC15 receptor and offers a promising pathway to develop new drugs to prevent viral infection from coronaviruses like COVID-19 or deal with fibrosis in the lungs."
NATURE STUDY: NEW ANTIBODY NASAL SPRAY MAY INHIBIT COVID 19, BA AND XBB VARIANTS
March 2023
"TriSb92 could be useful as a nasal spray for protecting susceptible individuals from SARS-CoV-2 infection."
Next steps include trials.